Published in Expert Opin Biol Ther on August 01, 2007
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One (2010) 1.03
Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum Gene Ther (2009) 1.00
Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics (2016) 0.93
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Front Immunol (2016) 0.84
Regulatory T cells, derived from naïve CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation (2005) 1.86
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood (2003) 1.70
Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest (2008) 1.68
CD3 limits the efficacy of TCR gene therapy in vivo. Blood (2011) 1.55
Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood (2011) 1.55
DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood (2008) 1.51
Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol (2010) 1.38
Monoclonal T-cell receptors: new reagents for cancer therapy. Mol Ther (2007) 1.34
Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci U S A (2009) 1.34
Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med (Berl) (2008) 1.28
Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat Biotechnol (2004) 1.26
A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A (2005) 1.25
Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood (2005) 1.24
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol (2012) 1.17
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Generation of tumor-specific T-cell therapies. Blood Rev (2005) 1.11
Challenges in T cell receptor gene therapy. J Gene Med (2012) 1.09
Optimisation of ultrasound-mediated gene transfer (sonoporation) in skeletal muscle cells. Ultrasound Med Biol (2004) 1.07
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood (2002) 1.05
Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation (2003) 1.04
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica (2009) 1.00
Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood (2011) 0.97
Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res (2006) 0.97
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res (2005) 0.94
Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J Immunol (2007) 0.93
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood (2004) 0.93
Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins. Front Oncol (2012) 0.92
Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology (2010) 0.91
Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother (2011) 0.91
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine. Cancer Immunol Immunother (2011) 0.90
Effect of vectors on human endothelial cell signal transduction: implications for cardiovascular gene therapy. Arterioscler Thromb Vasc Biol (2005) 0.90
Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood (2005) 0.89
Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology (2013) 0.88
CD8alpha/alpha homodimers fail to function as co-receptor for a CD8-dependent TCR. Eur J Immunol (2007) 0.88
Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol (2011) 0.88
Membrane IgE binds and activates Fc epsilon RI in an antigen-independent manner. J Immunol (2005) 0.88
Immunomodulation in the treatment of haematological malignancies. Clin Exp Med (2009) 0.87
WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis (2007) 0.85
Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res (2004) 0.85
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood (2002) 0.84
Efficient folding of the FcepsilonRI alpha-chain membrane-proximal domain D2 depends on the presence of the N-terminal domain D1. J Mol Biol (2002) 0.84
Hypothesis: a novel route for immortalization of epithelial cells by Epstein-Barr virus. Oncogene (2002) 0.83
IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer. Clin Cancer Res (2009) 0.81
Enhancing immune responses for cancer therapy. Cell Mol Immunol (2007) 0.80
A minimal receptor-Ig chimera of human FcepsilonRI alpha-chain efficiently binds secretory and membrane IgE. Protein Eng (2002) 0.79
Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner. Mol Immunol (2007) 0.79
Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy. Expert Opin Biol Ther (2005) 0.78
Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A. Br J Haematol (2014) 0.78
Therapeutic potential of Tregs to treat rheumatoid arthritis. Semin Immunol (2011) 0.78
A large-scale computational study of inhibitor risk in non-severe haemophilia A. Br J Haematol (2014) 0.77
Immunotherapy with CTL restricted by nonself MHC. Methods Mol Med (2005) 0.77
Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors. J Immunother (2009) 0.76
Anti-idiotypic DNA vaccines for B-cell lymphoma therapy. Front Biosci (2002) 0.76
Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2. Immunology (2008) 0.76
A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One (2007) 0.76
Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost (2015) 0.76
Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc Natl Acad Sci U S A (2011) 0.75
Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design. Mol Med (2007) 0.75
Burkitt's lymphoma: maximising the use of fine needle aspirates by long-term preservation for diagnosis and research. Trans R Soc Trop Med Hyg (2010) 0.75
The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. Thromb Haemost (2015) 0.75
T cell gene-engineering to enhance GVT and suppress GVHD. Best Pract Res Clin Haematol (2011) 0.75
Comparison of the frequency of peptide-specific cytotoxic T lymphocytes restricted by self- and allo-MHC following in vitro T cell priming. Int Immunol (2002) 0.75